NCT07835867Not yet recruiting
Individualized Exercise Training in Cardiac Amyloidosis
Graded Exercise Training for Individualized Treatment in Cardiac Amyloidosis: GET-FIT Cardiac Amyloidosis Study
Source: ClinicalTrials.gov · Last updated 23 Sept 2026
Brief summary (registry, in English)
Numerous clinical trials have demonstrated that transthyretin (TTR)-directed medical therapies can reduce the rate of functional decline in patients with transthyretin cardiac amyloidosis (ATTR-CM). However, patients treated with these therapies often experience a progressive reduction in exercise capacity despite treatment. Further, no randomized controlled trials (RCTs) have assessed the effects of exercise intervention in patients with ATTR-CM receiving TTR-directed therapy.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 17 Sept 2026
- Start date
- 15 Sept 2026
- Primary completion date
- 30 Jul 2028
- Lead sponsor
- Oregon Health and Science University
- Diseases
- Amyloidosis
- NCT number
- NCT07835867
What you commit to
- Study type: Interventional
- Planned participants: 60
- From 15 Sept 2026 to the primary completion date, 30 Jul 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Sustained ventricular arrhythmias or ICD shock within 6 months
- Recent acute coronary syndrome or coronary artery bypass \< 6 months
- Recent cardiac medication changes for management of cardiomyopathy
Other
- Severe valvular stenosis
- Pregnancy
- Large pericardial effusion
- Recent acute myocarditis (\< 3 months)
- Patients with investigational intracardiac devices
Who the study is looking for
- Clinical diagnosis of ATTR-cardiac amyloidosis
- Able to perform endurance and resistance exercise
- Currently on stable dose of TTR-directed therapy, if on therapy
- Adequate clinical stability has been achieved (in the judgment of the investigator) to allow participation in study assessments and intervention.
- Signed informed consent indicating that the patient understands the purpose of the study, the procedures required and is willing to participate
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.